SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

30 Oct 2021 Evaluate
The turnover soared 52.98% to Rs. 1744.28 millions for the September 2021 quarter as compared to Rs. 1140.19 millions during the corresponding quarter last year.A comparatively good net profit growth of 44.64% to Rs. 247.27 millions was reported for the quarter ended September 2021 compared to Rs. 170.96 millions of previous same quarter.The company reported a good operating profit of 387.51 millions compared to 253.56 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 1744.28 1140.19 52.98 3074.58 2280.38 34.83 4655.13 4419.51 5.33
Other Income 59.87 69.51 -13.87 138.82 139.02 -0.14 176.83 370.01 -52.21
PBIDT 387.51 253.56 52.83 725.77 507.11 43.12 1091.43 1371.68 -20.43
Interest 5.35 15.20 -64.80 18.35 30.40 -39.64 41.94 66.24 -36.68
PBDT 382.16 238.36 60.33 707.42 476.71 48.40 1049.49 1305.44 -19.61
Depreciation 34.46 34.29 0.50 69.27 68.58 1.01 137.62 88.31 55.84
PBT 347.70 204.07 70.38 638.15 408.13 56.36 911.87 1217.13 -25.08
TAX 100.43 33.11 203.32 174.30 66.22 163.21 236.86 293.79 -19.38
Deferred Tax -8.54 -6.38 33.86 1.32 -12.76 -110.34 11.69 -25.29 -146.22
PAT 247.27 170.96 44.64 463.85 341.91 35.66 675.01 923.34 -26.89
Equity 103.51 103.15 0.35 103.51 103.15 0.35 103.15 103.15 0.00
PBIDTM(%) 22.22 22.24 -0.10 23.61 22.24 6.15 23.45 31.04 -24.46

Bliss GVS Pharma Share Price

253.40 -4.95 (-1.92%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×